Yvonne Jongejan: Allele-Selective Silencing Therapy for VWD and Thrombotic Disorders
Yvonne Jongejan, Postdoctoral researcher at Leiden University Medical Center, reposted from RPTH Journal on LinkedIn:
”A nice overview in RPTH of the work Annika de Jong, Noa Linthorst, Isabel Bär, Jeroen Eikenboom and myself have done and are still doing to develop an allele-selective silencing therapy for von Willebrand disease and thrombotic disorders.”
Quoting RPTH Journal‘s post about a recent article by Jeroen Eikenboom et al:
”What if the future of VWF therapy is not replacing the protein, but silencing the wrong allele?
This RPTH State-of-the-Art review highlights allele-selective VWF silencing: a precision siRNA strategy designed to switch off only one VWF allele.
For dominant-negative VWD, this could remove mutant VWF and restore healthier multimer formation. For thrombotic disorders linked to high VWF, it may offer a controlled way to lower VWF without pushing patients into bleeding risk.
One allele. Two clinical directions. A new precision-medicine angle for VWF biology.”
Title: Allele-selective von Willebrand factor silencing
Authors: Jeroen Eikenboom, Noa Linthorst, Yvonne Jongejan
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients